SCHEMBL3947747

SCHEMBL3947747

CC(C=O)=C(c1ccc(C(F)(F)F)cc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.51
NR4A2 P43354 1/20 0.51
NR4A3 Q92570 1/20 0.51
CES2 O00748 2/20 0.50
CES1 P23141 2/20 0.50
PTGS1 P23219 4/20 0.45
PTGS2 P35354 2/20 0.45
NQO2 P16083 1/20 0.45
SRD5A2 P31213 1/20 0.44
GSK3B P49841 2/20 0.43
PTPN1 P18031 2/20 0.43
CYP1A1 P04798 2/20 0.41
CYP1B1 Q16678 2/20 0.41
TRPV1 Q8NER1 1/20 0.41
MAOB P27338 2/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4098802 0.79 NR4A1 (0.58) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL3948491 0.79 NR4A1 (0.58) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL9855705 0.78 CES2 (0.44) CES2CES1PTGS1PTGS2PTPN1
Acetaldehyde SCHEMBL5737539 0.74 NR4A1 (0.62) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL294902 0.74 CES2 (0.61) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL7799695 0.73 NR4A1 (0.61) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL7804956 0.73 NR4A1 (0.61) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL72091 0.73 CES2 (0.67) NR4A1NR4A2NR4A3CES2CES1
SCHEMBL2222239 0.73 ALDH1A1 (0.50) CES2CES1PTGS2ALDH1A1
Water SCHEMBL27244063 0.72 CES2 (0.59) NR4A1NR4A2NR4A3CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 NR4A1 93/4885NR4A2 672/4885NR4A3 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.